Live price temporarily unavailable.
Anebulo Pharmaceuticals (ANEB) is a Health Care company. Latest news and coverage below.
| FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Operating income | −$3.61M | −$6.83M | −$11.8M | −$8.31M | −$9.22M |
| Net income | −$30.3M | −$6.83M | −$11.7M | −$8.20M | −$8.48M |
| EPS (diluted) | −$2.83 | $0.29 | −$0.47 | −$0.32 | −$0.25 |
| Balance sheet | |||||
| Cash and equivalents | $20.0M | $14.5M | $11.2M | $3.09M | $11.6M |
| Total assets | $21.7M | $15.6M | $11.7M | $4.07M | $12.1M |
| Total liabilities | $241.6K | $512.5K | $1.07M | $260.6K | $487.7K |
| Shareholders' equity | $21.4M | $15.1M | $10.6M | $3.81M | $11.7M |
| Cash flow | |||||
| Operating cash flow | −$4.87M | −$5.44M | −$9.68M | −$8.09M | −$6.35M |
| Q3 FY24Mar 2024 | Q4 FY24†Jun 2024 | Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$1.66M | −$1.34M | −$2.41M | −$2.59M | −$1.89M | −$2.33M | −$2.26M | −$2.62M |
| Net income | −$1.65M | −$1.35M | −$2.20M | −$2.46M | −$1.68M | −$2.14M | −$2.16M | −$2.00M |
| EPS (diluted) | −$0.06 | −$0.05 | −$0.08 | −$0.09 | −$0.04 | −$0.04 | −$0.05 | −$0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $5.15M | $3.09M | $1.40M | $15.0M | $13.3M | $11.6M | $10.4M | $9.04M |
| Total assets | $6.00M | $4.07M | $2.47M | $15.8M | $14.0M | $12.1M | $10.7M | $9.42M |
| Total liabilities | $1.01M | $260.6K | $569.2K | $878.8K | $546.0K | $487.7K | $963.8K | $1.49M |
| Shareholders' equity | $4.99M | $3.81M | $1.90M | $15.0M | $13.5M | $11.7M | $9.74M | $7.94M |
| Cash flow | ||||||||
| Operating cash flow | −$1.50M | −$2.05M | −$1.69M | −$1.41M | −$1.60M | −$1.65M | −$1.27M | −$1.31M |
From Anebulo Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Anebulo Pharmaceuticals in our feed yet.